{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:07:26Z","timestamp":1762506446142,"version":"build-2065373602"},"reference-count":62,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.anai.2014.06.031","type":"journal-article","created":{"date-parts":[[2014,11,4]],"date-time":"2014-11-04T19:15:50Z","timestamp":1415128550000},"page":"513-519","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Potential benefit of omalizumab in respiratory diseases"],"prefix":"10.1016","volume":"113","author":[{"given":"Matteo","family":"Bonini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Di Maria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierluigi","family":"Paggiaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GianEnrico","family":"Senna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Triggiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio Walter","family":"Canonica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2014.06.031_bib1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.anai.2013.12.013","article-title":"Biologic targeted therapy in allergic asthma","volume":"112","author":"Bice","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2014.06.031_bib2","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1365-2222.2005.02191.x","article-title":"Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy","volume":"35","author":"Holgate","year":"2005","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.anai.2014.06.031_bib3","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1046\/j.1365-2222.2003.01674.x","article-title":"Relationships of allergic sensitization, total immunoglobulin E and blood eosinophils to asthma severity in children of the EGEA Study","volume":"33","author":"Siroux","year":"2003","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.anai.2014.06.031_bib4","first-page":"CD003559","article-title":"Omalizumab for asthma in adults and children","volume":"1","author":"Normansell","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.anai.2014.06.031_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17520","article-title":"Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation","volume":"17","author":"Norman","year":"2013","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.anai.2014.06.031_bib6","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1365-2222.2009.03214.x","article-title":"Safety and tolerability of omalizumab","volume":"39","author":"Corren","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.anai.2014.06.031_bib7","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1164\/ajrccm.155.6.9196082","article-title":"The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects","volume":"155","author":"Fahy","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.anai.2014.06.031_bib8","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.4049\/jimmunol.167.3.1290","article-title":"Minimal requirements for IgEmediated regulation of surface Fc epsilon RI","volume":"167","author":"Borkowski","year":"2001","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.anai.2014.06.031_bib9","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jaci.2009.10.021","article-title":"Decreases in human dendritic cell-dependent T(H)2-like responses after acute in\u00a0vivo IgE neutralization","volume":"125","author":"Schroeder","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2014.06.031_bib10","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.rmed.2010.07.011","article-title":"Omalizumab-induced decrease of Fc\u03beRI expression in patients with severe allergic asthma","volume":"104","author":"Chanez","year":"2010","journal-title":"Respir Med"},{"key":"10.1016\/j.anai.2014.06.031_bib11","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.imbio.2007.03.001","article-title":"The pro- and anti-inflammatory properties of human antigenpresenting cells expressing the high affinity receptor for IgE (Fc epsilon RI)","volume":"212","author":"Bieber","year":"2007","journal-title":"Immunobiology"},{"key":"10.1016\/j.anai.2014.06.031_bib12","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jaci.2010.01.020","article-title":"Anti-IgE therapy results in decreased myeloid dendritic cells in asthmatic airways","volume":"125","author":"Chand","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2014.06.031_bib13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.it.2004.10.010","article-title":"Mast cells and basophils: friends as well as foes in bronchial asthma?","volume":"26","author":"Marone","year":"2005","journal-title":"Trends Immunol"},{"key":"10.1016\/j.anai.2014.06.031_bib14","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s11882-013-0338-z","article-title":"The role of interleukin-33 in rhinitis","volume":"13","author":"Rogala","year":"2013","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.anai.2014.06.031_bib15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000250436","article-title":"Reduced FcepsilonRI-mediated release of asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy","volume":"151","author":"Oliver","year":"2010","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.anai.2014.06.031_bib16","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.jaci.2013.04.056","article-title":"Omalizumab increases the intrinsic sensitivity of human basophils to IgE-mediated stimulation","volume":"132","author":"Macglashan","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2014.06.031_bib17","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.4049\/jimmunol.1102689","article-title":"Soluble CD23 controls IgE synthesis and homeostasis in human B cells","volume":"188","author":"Cooper","year":"2012","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.anai.2014.06.031_bib18","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.anai.2013.04.011","article-title":"Efficacy of omalizumab in asthmatic patients with IgE levels above 700 IU\/mL: a retrospective study","volume":"110","author":"Maselli","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2014.06.031_bib19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jaci.2009.06.011","article-title":"Total IgE levels and asthma prevalence in the US population: results from the National Health and Nutrition Examination Survey 2005\u20132006","volume":"124","author":"Gergen","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2014.06.031_bib20","first-page":"243","article-title":"Asthma phenotypes and endotypes: an evolving paradigm for classification","volume":"15","author":"Corren","year":"2013","journal-title":"Discov Med"},{"key":"10.1016\/j.anai.2014.06.031_bib21","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1378\/chest.12-0598","article-title":"T\u00a0helper 17 cells in airway diseases: from laboratory bench to bedside","volume":"143","author":"Halwani","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.anai.2014.06.031_bib22","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/ni.1892","article-title":"The many paths to asthma: phenotype shaped by innate and adaptive immunity","volume":"11","author":"Kim","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.anai.2014.06.031_bib23","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3109\/02770903.2012.757780","article-title":"Effects of omalizumab in nonatopic asthma: results from a Spanish multicenter registry","volume":"50","author":"de Llano","year":"2013","journal-title":"J\u00a0Asthma"},{"key":"10.1016\/j.anai.2014.06.031_bib24","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1378\/chest.12-1961","article-title":"A\u00a0proof of concept randomized-controlled trial of omalizumab in patients with severe difficult to control nonatopic asthma","volume":"144","author":"Garcia","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.anai.2014.06.031_bib25","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2014.06.031_bib26","first-page":"425","article-title":"Allergen-specific immunoglobulin E in the skin and nasal mucosa of symptomatic and asymptomatic children sensitized to aeroallergens","volume":"20","author":"Fuiano","year":"2010","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.anai.2014.06.031_bib27","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jaci.2012.05.012","article-title":"Specific IgE against Staphylococcus aureus enterotoxins: an independent risk factor for asthma","volume":"130","author":"Bachert","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2014.06.031_bib28","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1517\/14712598.2013.795943","article-title":"Omalizumab for treatment of allergic rhinitis","volume":"13","author":"Vashisht","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.anai.2014.06.031_bib29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1939-4551-6-11","article-title":"Seeking allergy when it hides: which are the best fitting tests?","volume":"6","author":"Incorvaia","year":"2013","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.anai.2014.06.031_bib30","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1001\/jama.286.23.2956","article-title":"Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial","volume":"286","author":"Casale","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.anai.2014.06.031_bib31","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1067\/mai.2000.108310","article-title":"Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis","volume":"106","author":"Adelroth","year":"2000","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2014.06.031_bib32","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2332\/allergolint.55.379","article-title":"Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis","volume":"55","author":"Okubo","year":"2006","journal-title":"Allergol Int"},{"key":"10.1016\/j.anai.2014.06.031_bib33","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S1081-1206(10)62171-0","article-title":"Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis","volume":"91","author":"Chervinsky","year":"2003","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2014.06.031_bib34","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1398-9995.2007.01584.x","article-title":"Frequency and impact of allergic rhinitis in asthma patients in everyday general medical practice: a French observational cross-sectional study","volume":"63","author":"Magnan","year":"2008","journal-title":"Allergy"},{"issue":"suppl 86","key":"10.1016\/j.anai.2014.06.031_bib35","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1398-9995.2007.01620.x","article-title":"Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)","volume":"63","author":"Bousquet","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2014.06.031_bib36","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1398-9995.2004.00550.x","article-title":"Efficacy and tolerability of antiimmunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR","volume":"59","author":"Vignola","year":"2004","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2014.06.031_bib37","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1398-9995.2008.01846.x","article-title":"Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis","volume":"64","author":"Humbert","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2014.06.031_bib38","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.jaci.2013.02.036","article-title":"Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology","volume":"131","author":"Akdis","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2014.06.031_bib39","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/all.12054","article-title":"Local receptor revision and class switching to IgE in chronic rhinosinusitis with nasal polyps","volume":"68","author":"Gevaert","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2014.06.031_bib40","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1067\/mai.2001.112374","article-title":"Total and specific IgE in nasal polyps is related to local eosinophilic inflammation","volume":"107","author":"Bachert","year":"2001","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2014.06.031_bib41","doi-asserted-by":"crossref","first-page":"428","DOI":"10.2500\/ajr.2007.21.3060","article-title":"The role of anti-IgE immunoglobulin therapy in nasal polyposis: a pilot study","volume":"21","author":"Penn","year":"2007","journal-title":"Am J Rhinol"},{"key":"10.1016\/j.anai.2014.06.031_bib42","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1136\/thx.2010.152835","article-title":"Efficacy of omalizumab in the treatment of nasal polyps","volume":"66","author":"Vennera Mdel","year":"2011","journal-title":"Thorax"},{"key":"10.1016\/j.anai.2014.06.031_bib43","first-page":"158","article-title":"Recalcitrant nasal polyposis: achievement of total remission following treatment with omalizumab","volume":"19","author":"Guglielmo","year":"2009","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.anai.2014.06.031_bib44","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.anai.2013.01.024","article-title":"Efficacy of omalizumab in eosinophilic chronic rhinosinusitis patients with asthma","volume":"110","author":"Tajiri","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2014.06.031_bib45","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4193\/Rhino09.144","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis","volume":"48","author":"Pinto","year":"2010","journal-title":"Rhinology"},{"key":"10.1016\/j.anai.2014.06.031_bib46","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ccm.2012.02.003","article-title":"Allergic bronchopulmonary aspergillosis","volume":"33","author":"Bains","year":"2012","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.anai.2014.06.031_bib47","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1136\/thx.2004.035519","article-title":"Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody","volume":"62","author":"van der Ent","year":"2007","journal-title":"Thorax"},{"key":"10.1016\/j.anai.2014.06.031_bib48","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/ppul.20804","article-title":"Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis","volume":"43","author":"Zirbes","year":"2008","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.anai.2014.06.031_bib49","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.prrv.2012.11.004","article-title":"Omalizumab in the management of steroid dependent allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis","volume":"14","author":"Wong","year":"2013","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.anai.2014.06.031_bib50","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1398-9995.2009.02147.x","article-title":"Steroid dependency despite omalizumab treatment of ABPA in cystic fibrosis","volume":"65","author":"Brinkmann","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2014.06.031_bib51","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/ppul.20907","article-title":"Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab)","volume":"43","author":"Kanu","year":"2008","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.anai.2014.06.031_bib52","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.07.2008.0379","article-title":"Omalizumab for exacerbations of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis","author":"Lebecque","year":"2009","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.anai.2014.06.031_bib53","first-page":"88","article-title":"Management of patients with cystic fibrosis and allergic bronchopulmonary aspergillosis using anti-immunoglobulin E therapy (omalizumab)","volume":"17","author":"Elmallah","year":"2012","journal-title":"J\u00a0Pediatr Pharmacol Ther"},{"key":"10.1016\/j.anai.2014.06.031_bib54","unstructured":"Homma T, Kurokawa M, Matsukura S, Yamaguchi M, Adachi M. Anti-IgE therapy for allergic bronchopulmonary aspergillosis [published online ahead of print November 28, 2013]. J Microbiol Immunol Infect. PII: S1684-1182(13) 00197\u20137."},{"key":"10.1016\/j.anai.2014.06.031_bib55","first-page":"145","article-title":"A\u00a0case of allergic bronchopulmonary aspergillosis treated with omalizumab","volume":"22","author":"Sastre","year":"2012","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.anai.2014.06.031_bib56","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2147\/JAA.S34579","article-title":"Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab","volume":"5","author":"Collins","year":"2012","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.anai.2014.06.031_bib57","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/thx.2010.153312","article-title":"Effects of omalizumab in Aspergillus-associated airway disease","volume":"66","author":"P\u00e9rez-de-Llano","year":"2011","journal-title":"Thorax"},{"key":"10.1016\/j.anai.2014.06.031_bib58","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/j.1398-9995.2011.02599.x","article-title":"Allergic bronchopulmonary aspergillosis and omalizumab","volume":"66","author":"Tillie-Leblond","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2014.06.031_bib59","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jaci.2008.09.050","article-title":"Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations","volume":"123","author":"Slavin","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2014.06.031_bib60","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1365-2125.2011.03962.x","article-title":"Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE","volume":"72","author":"Lowe","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.anai.2014.06.031_bib61","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0091-6749(97)70202-1","article-title":"Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis","volume":"100","author":"Casale","year":"1997","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2014.06.031_bib62","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2222.2007.02894.x","article-title":"Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis","volume":"38","author":"Nagakura","year":"2008","journal-title":"Clin Exp Allergy"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120614006000?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120614006000?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:11:17Z","timestamp":1761052277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120614006000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S1081120614006000"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2014.06.031","relation":{},"ISSN":["1081-1206"],"issn-type":[{"type":"print","value":"1081-1206"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential benefit of omalizumab in respiratory diseases","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2014.06.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}